Clinical trial · Interventional
Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
Multi-center Study Evaluating OraVescent Fentanyl Citrate for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
NCT00105287CI-TRIAL-00014473completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl when used long-term to relieve breakthrough pain in opioid tolerant cancer patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Pain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| OraVescent fentanyl (OVF) | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Documented diagnosis of a malignant solid tumor or hematological malignancy causing cancer related pain * Currently taking around the clock opioid therapy for pain * Experience on average, 1-4 breakthrough pain episodes per day Exclusion Criteria: * Opioid or fentanyl intolerance * Sleep apnea or active brain metastases with increased intracranial pressure * COPD (chronic obstructive pulmonary disease); cardiopulmonary disease; heart disease
References
Publications (0)
Data not yet available
No reference posted for this study.